Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JWCAR029 in Relapsed/Refractory Mantle Cell Lymphoma
NCT04718883Phase 2Active, not recruiting
- Sponsor
- Shanghai Ming Ju Biotechnology
- Start
- Jan 2021
- Primary completion
- Oct 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of relmacabtagene autoleucel in mantle cell lymphoma (MCL), sponsored by Shanghai Ming Ju Biotechnology. Started Jan 2021; status: active, not recruiting.
02
Drugs
relmacabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04718883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718883.